Inotuzumab ozogamicin is an antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL). Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (Gemtuzumab ozogamicin), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukemia. Inotuzumab ozogamicin consists of a recombinant humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethyl hydrazide, which is a potent DNA-binding cytotoxic agent [rx]. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by the EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relapsing conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing long periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy [rx].
Mechanism of action
Inotuzumab ozogamicin is comprised of cytotoxic antibiotic N-acetyl-gamma-calicheamicin dimethyl hydrazide attached to a humanized monoclonal IgG4 antibody via 4-(4 acetylphenoxy) butanoic acid (acetyl butyrate) linker. The drug exerts a potent cytotoxic effect against CD22+ B-cell lymphoma when the antibody binds to the CD22 receptor on the surface of B cells. The drug-CD22 complex is rapidly internalized into the cell, forming an endosome that subsequently fuses with lysosomes. N-acetyl-gamma-calicheamicin dimethyl hydrazide is then intracellularly released into the acidic environment. N-acetyl-gamma-calicheamicin dimethyl hydrazide is a calicheamicin derivative, which is naturally produced by the bacterium Micromonospora Tinospora, and is toxic to the body when not bound to the antibody. It mediates apoptosis of the cell by binding to the minor groove of DNA in a sequence-specific manner and undergoing a structural change to generate diradicals [rx]. These changes abstract hydrogen ions from the phosphodiester bonds of double-stranded DNA, resulting in breaks and cell apoptosis [rx].
Indications
- Indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukemia (ALL).
- Refractory B-cell precursor acute lymphoblastic leukemia
- Relapsed B cell precursor Acute lymphoblastic leukemia
- Inotuzumab ozogamicin is used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Use in Cancer
Inotuzumab ozogamicin is approved to treat:
- B-cell acute lymphoblastic leukemia (ALL). It is used in adults whose cancer has relapsed or is refractory (does not respond to treatment).
Inotuzumab ozogamicin is also being studied in the treatment of other types of cancer.
Contraindications
- a bad infection
- acute leukemia
- low amount of magnesium in the blood
- low amount of calcium in the blood
- low amount of sodium in the blood
- low amount of potassium in the blood
- hemolytic uremic syndrome, a condition that affects the kidney and the blood
- anemia
- decreased blood platelets
- low levels of white blood cells
- a painful condition that affects the nerves in the legs and arms called peripheral neuropathy
- sudden blindness and pain upon moving the eye
- ototoxicity, damage to the inner ear that affects hearing or balance
- hearing loss
- a heart attack
- a clot in the lung
- a stroke
- inflammation of blood vessels in the brain or spinal cord
- Raynaud’s phenomenon, a condition where blood vessels constrict too much with coldness or stress
- blood clot in a deep vein of the extremities
- thrombotic thrombocytopenic purpura, a type of blood disorder
- decreased kidney function
- vomiting
- amount of uric acid in the blood
- pregnancy
- a patient who is producing milk and breastfeeding
- TPMT poor metabolizer
- a type of brain disorder called posterior reversible encephalopathy syndrome
- a clot in the aorta
- kidney disease with likely reduction in kidney function
Dosage
Strengths: 0.9 mg
Acute Lymphoblastic Leukemia
Cycle 1 (total dose is 1.8 mg/m2/cycle):
- Day 1: 0.8 mg/m2 IV
- Day 8: 0.5 mg/m2 IV
- Day 15: 0.5 mg/m2 IV
Duration of therapy: Cycle 1 is 21 days in duration, but may be extended to 28 days (7-day therapy-free interval starting on Day 21) if the patient achieves a complete remission (CR) or complete remission with incomplete hematologic recovery (CRi), and/or to allow for recovery from toxicity
Subsequent Cycles:
For patients who achieve a CR or CRi (total dose is 1.5 mg/m2/cycle):
- Day 1: 0.5 mg/m2 IV
- Day 8: 0.5 mg/m2 IV
- Day 15: 0.5 mg/m2 IV
Duration of therapy: 28 days (7-day therapy free interval starting on Day 21)
OR
For patients who do not achieve a CR or CRi (total dose is 1.8 mg/m2/cycle):
- Day 1: 0.8 mg/m2 IV
- Day 8: 0.5 mg/m2 IV
- Day 15: 0.5 mg/m2 IV
Duration of therapy: 28 days (7-day therapy free interval starting on Day 21); patients who do not achieve a CR or CRi within 3 cycles should discontinue therapy
For patients proceeding to hematopoietic stem cell transplant (HSCT):
- Duration of therapy: 2 cycles; a third cycle may be considered for those patients who do not achieve CR or CRi and minimal residual disease (MRD) negativity after 2 cycles
For patients not proceeding to HSCT:
- Duration of therapy: Additional cycles of treatment, up to a maximum of 6 cycles, may be administered.
- Premedicate patients with a corticosteroid, an antipyretic, and an antihistamine prior to dosing.
- Infuse for 1 hour at a rate of 50 mL/hr.
- Doses on days 8 and 15 may be varied by plus or minus 2 days (maintain a minimum of 6 days between doses).
- Complete remission (CR) is defined as less than 5% blasts in bone marrow and the absence of peripheral blood leukemic blasts, full recovery of peripheral blood counts [platelets 100 x 10(9)/L or greater and absolute neutrophil count (ANC) 1 x 10(9)/L or greater] and resolution of any extramedullary disease.
- Complete remission with incomplete hematologic recovery (CRi) is defined as less than 5% blasts in bone marrow and the absence of peripheral blood leukemic blasts, full recovery of peripheral blood counts [platelets less than 100 x 10(9)/L and ANC less than 1 x 10(9)/L] and resolution of any extramedullary disease.
- For patients with circulating lymphoblasts, cytoreduction with a combination of hydroxyurea, steroids, and/or vincristine to a peripheral blast count of 10,000/mm3 or less is recommended prior to the first dose.
- Observe patients for infusion reactions during and for at least 1 hour after the end of the infusion.
Renal Dose Adjustments
- Mild (CrCl 60 to 89 mL/min), moderate (CrCl 30 to 59 mL/min), or severe (CrCl 15 to 29 mL/min) renal impairment: No adjustment recommended.
End-stage renal disease (CrCl less than 15 mL/min): Data not available
Dose Adjustments
Dose Adjustments for Hematologic Toxicities:
- If ANC is 1 x 10(9)/L or greater prior to starting of therapy:
- If ANC decreases, interrupt the next cycle of therapy until recovery of ANC to 1 x 10(9)/L or greater.
- Discontinue therapy if low ANC persists for greater than 28 days and is probably related to this drug.
If the platelet count is 50 x 10(9)/L or greater prior to starting therapy
- If the platelet count decreases, interrupt the next cycle of therapy until the platelet count recovers to 50 x 10(9)/L or greater.
- Discontinue therapy if low platelet count persists for greater than 28 days and is probably related to this drug.
If ANC is less than 1 x 10(9)/L and/or platelet count is less than 50 x 10(9)/L prior to start of therapy:
- If ANC or platelet count decreases interrupt the next cycle of therapy until at least one of the following occurs:
1) ANC and platelet counts recover to at least baseline levels for the prior cycle
OR
2) ANC recovers to 1 x 10(9)/L or greater and platelet count recovers to 50 x 10(9)/L or greater
OR
3) Stable or improved disease (based on most recent bone marrow assessment) and the ANC and platelet count decrease is due to the underlying disease (not considered to have been caused by this drug).
Dose Adjustments for Nonhematologic Toxicities:
- Veno-occlusive disease (VOD) or other severe liver toxicity: Permanently discontinue therapy.
- Total bilirubin greater than 1.5 x upper limit of normal (ULN) and AST/ALT greater than 2.5 x ULN: Interrupt therapy until recovery of total bilirubin to 1.5 x ULN or less and AST/ALT to 2.5 x ULN or less prior to each dose unless due to Gilbert’s syndrome or hemolysis; permanently discontinue therapy if total bilirubin does not recover to 1.5 x ULN or less or AST/ALT does not recover to 2.5 x ULN or less.
- Infusion-related reaction: Interrupt the infusion and manage medically; depending on the severity of the reaction, consider discontinuation of therapy and administration of steroids and antihistamines; for severe or life-threatening infusion reactions, permanently discontinue therapy.
- Nonhematologic toxicity Grade 2 or greater: Interrupt therapy until recovery to Grade 1 or pretreatment Grade levels prior to each dose.
Dose Adjustments Depending on Duration of Dosing Interruption Due to Nonhematologic Toxicity:
- Interruption of less than 7 days (within a cycle): Interrupt the next dose (maintain a minimum of 6 days between doses).
- Interruption of 7 days or more: Omit the next dose in the cycle.
- Interruption of 14 days or more: After recovery, decrease the dose by 25% for the next cycle; if further dose modification is required, reduce the number of doses to 2 per cycle for subsequent cycles; if a 25% decrease in the total dose followed by a decrease to 2 doses per cycle is not tolerated, then permanently discontinue therapy.
- Interruption of more than 28 days: Consider permanent discontinuation of therapy.
Side Effects
The Most Common
- dizziness
- lightheadedness
- fever, chills, cough, or other signs of infection
- unusual bleeding or bruising
- black and tarry stools
- red blood in stools
- pale skin
- fatigue
More common
- fever, weakness, cold, or flu symptoms;
- cough, trouble breathing;
- swollen gums, mouth sores;
- pale skin, easy bruising, skin sores;
- a headache with chest pain and severe dizziness, fainting, fast or pounding heartbeats;
- signs of liver problems–upper stomach pain, jaundice (yellowing of the skin or eyes), or rapid weight gain, swelling in your arms or legs, painful swelling in your midsection; or
- unusual bleeding gums, abnormal vaginal bleeding, blood in your urine or stools, coughing up blood or vomit that looks like coffee grounds.
Rare
- Black, tarry stools
- bleeding gums
- blood in the urine or stools
- chest pain
- chills
- cough or hoarseness
- coughing up blood
- difficulty in breathing or swallowing
- dizziness
- fever
- headache
- increased menstrual flow or vaginal bleeding
- lower back or side pain
- nosebleeds
- painful or difficult urination
- pale skin
- paralysis
- pinpoint red spots on the skin
- prolonged bleeding from cuts
- red or dark brown urine
- sore throat
- sores, ulcers, or white spots on the lips or in the mouth
- swollen glands
- troubled breathing with exertion
- unusual bleeding or bruising
- unusual tiredness or weakness
- yellow eyes or skin
Drug Interaction
| DRUG | INTERACTION |
|---|---|
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Inotuzumab ozogamicin. |
| Abemaciclib | The serum concentration of Abemaciclib can be increased when it is combined with Inotuzumab ozogamicin. |
| Abrocitinib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Abrocitinib. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Inotuzumab ozogamicin. |
| Aducanumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Aducanumab. |
| Afatinib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Afatinib. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Inotuzumab ozogamicin. |
| Alirocumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Alirocumab. |
| Ambrisentan | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ambrisentan. |
| Amiodarone | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Amiodarone. |
| Amivantamab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Amivantamab. |
| Anifrolumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Anifrolumab. |
| Ansuvimab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ansuvimab. |
| Anthrax immune | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Anthrax immune globulin human. |
| Antilymphocyte | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Antilymphocyte immunoglobulin (horse). |
| Antithymocyte | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Inotuzumab ozogamicin. |
| Apalutamide | The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Apalutamide. |
| Apixaban | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Apixaban. |
| Arsenic trioxide | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Arsenic trioxide. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Articaine. |
| Asciminib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Asciminib. |
| Asfotase alfa | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Asfotase alfa. |
| Asunaprevir | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Asunaprevir. |
| Atezolizumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Atezolizumab. |
| Atoltivimab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Atoltivimab. |
| Avanafil | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Avanafil. |
| Avatrombopag | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Avatrombopag. |
| Avelumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Avelumab. |
| Axitinib | The serum concentration of Axitinib can be increased when it is combined with Inotuzumab ozogamicin. |
| Bamlanivimab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Bamlanivimab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Inotuzumab ozogamicin. |
| Bebtelovimab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Bebtelovimab. |
| Belantamab mafodotin | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Belantamab mafodotin. |
| Belimumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Belimumab. |
| Belinostat | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Belinostat. |
| Belumosudil | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Belumosudil. |
| Bendamustine | The serum concentration of Bendamustine can be increased when it is combined with Inotuzumab ozogamicin. |
| Benralizumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Benralizumab. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Benzocaine. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Benzyl alcohol. |
| Berotralstat | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Berotralstat. |
| Besilesomab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Besilesomab. |
| Betrixaban | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Betrixaban. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Inotuzumab ozogamicin. |
| Bezlotoxumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Bezlotoxumab. |
| Bimekizumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Bimekizumab. |
| Binimetinib | The serum concentration of Binimetinib can be increased when it is combined with Inotuzumab ozogamicin. |
| Bisoprolol | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Bisoprolol. |
| Blinatumomab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Blinatumomab. |
| Bortezomib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Bortezomib. |
| Bosutinib | The serum concentration of Bosutinib can be increased when it is combined with Inotuzumab ozogamicin. |
| Brentuximab | The serum concentration of Brentuximab vedotin can be increased when it is combined with Inotuzumab ozogamicin. |
| Brodalumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Brodalumab. |
| Brolucizumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Brolucizumab. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Bupivacaine. |
| Burosumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Burosumab. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Butacaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Butamben. |
| Cabazitaxel | The serum concentration of Cabazitaxel can be increased when it is combined with Inotuzumab ozogamicin. |
| Cabergoline | The serum concentration of Cabergoline can be increased when it is combined with Inotuzumab ozogamicin. |
| Canagliflozin | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Canagliflozin. |
| Canakinumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Canakinumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Caplacizumab. |
| Capmatinib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Capmatinib. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Inotuzumab ozogamicin. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Capsaicin. |
| Carfilzomib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Carfilzomib. |
| Carvedilol | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Carvedilol. |
| Casirivimab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Casirivimab. |
| Catumaxomab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Catumaxomab. |
| Cemiplimab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Cemiplimab. |
| Ceritinib | The serum concentration of Ceritinib can be increased when it is combined with Inotuzumab ozogamicin. |
| Certolizumab pegol | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Certolizumab pegol. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Inotuzumab ozogamicin. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Chloroprocaine. |
| Cilgavimab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Cilgavimab. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Cinchocaine. |
| Clarithromycin | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Clarithromycin. |
| Clobazam | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Clobazam. |
| Clofazimine | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Clofazimine. |
| Clomifene | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Clomifene. |
| Cobicistat | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Cobicistat. |
| Cobimetinib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Cobimetinib. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Cocaine. |
| Colchicine | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Colchicine. |
| Conivaptan | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Conivaptan. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| Copanlisib | The serum concentration of Copanlisib can be increased when it is combined with Inotuzumab ozogamicin. |
| Crizotinib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Crizotinib. |
| Curcumin | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Curcumin. |
| Cyclosporine | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Cyclosporine. |
| Dabigatran etexilate | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Dabigatran etexilate. |
| Dabrafenib | The serum concentration of Dabrafenib can be increased when it is combined with Inotuzumab ozogamicin. |
| Daclatasvir | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Daclatasvir. |
| Dacomitinib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Dacomitinib. |
| Dactinomycin | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Dactinomycin. |
| Daptomycin | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Daptomycin. |
| Daratumumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Daratumumab. |
| Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Inotuzumab ozogamicin. |
| Darolutamide | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Darolutamide. |
| Elotuzumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Elotuzumab. |
| Emapalumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Emapalumab. |
| Emicizumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Emicizumab. |
| Enasidenib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Enasidenib. |
| Enfortumab vedotin | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Enfortumab vedotin. |
| Entrectinib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Entrectinib. |
| Eptinezumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Eptinezumab. |
| Erdafitinib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Erdafitinib. |
| Erenumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Erenumab. |
| Ertugliflozin | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ertugliflozin. |
| Erythromycin | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Erythromycin. |
| Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Inotuzumab ozogamicin. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| Estetrol | Estetrol may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| Estradiol | Estradiol may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| Estriol | Estriol may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| Estrone | Estrone may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Ethyl chloride. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Etidocaine. |
| Etoposide | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Etoposide. |
| Everolimus | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Everolimus. |
| Evolocumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Evolocumab. |
| Fanolesomab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Fanolesomab. |
| Favipiravir | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Favipiravir. |
| Fedratinib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Fedratinib. |
| Fexofenadine | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Fexofenadine. |
| Filgotinib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Filgotinib. |
| Flibanserin | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Flibanserin. |
| Fluconazole | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Fluconazole. |
| Fostemsavir | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Fostemsavir. |
| Fremanezumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Fremanezumab. |
| Futibatinib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Futibatinib. |
| Galcanezumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Galcanezumab. |
| Gemcitabine | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Gemcitabine. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Inotuzumab ozogamicin. |
| Gilteritinib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Gilteritinib. |
| Glasdegib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Glasdegib. |
| Glecaprevir | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Glecaprevir. |
| Golimumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Golimumab. |
| Grazoprevir | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Grazoprevir. |
| Guselkumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Guselkumab. |
| Hepatitis B | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Inotuzumab ozogamicin. |
| cytomegalovirus | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Human cytomegalovirus immune globulin. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Inotuzumab ozogamicin. |
| immune globulin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Human Rho(D) immune globulin. |
| Human varicella-zoster | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Human varicella-zoster immune globulin. |
| Ibalizumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ibalizumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Inotuzumab ozogamicin. |
| Idarucizumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Idarucizumab. |
| Idelalisib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Idelalisib. |
| Imdevimab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Imdevimab. |
| Imipramine | The serum concentration of Imipramine can be increased when it is combined with Inotuzumab ozogamicin. |
| Imlifidase | The therapeutic efficacy of Inotuzumab ozogamicin can be decreased when used in combination with Imlifidase. |
| Indacaterol | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Indacaterol. |
| Inebilizumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Inebilizumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Inotuzumab ozogamicin. |
| Ipilimumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ipilimumab. |
| Isatuximab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Isatuximab. |
| Isavuconazole | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Isavuconazole. |
| Isavuconazonium | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Isavuconazonium. |
| Istradefylline | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Istradefylline. |
| Itraconazole | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Itraconazole. |
| Ketoconazole | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ketoconazole. |
| Lanadelumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Lanadelumab. |
| Lapatinib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Lapatinib. |
| Larotrectinib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Larotrectinib. |
| Lasmiditan | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Lasmiditan. |
| Ledipasvir | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ledipasvir. |
| Lefamulin | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Lefamulin. |
| Lemborexant | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Lemborexant. |
| Lenvatinib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Lenvatinib. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Levobupivacaine. |
| Levoketoconazole | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Levoketoconazole. |
| Levothyroxine | The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Levothyroxine. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Lidocaine. |
| Linagliptin | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Linagliptin. |
| Lomitapide | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Lomitapide. |
| Lonafarnib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Lonafarnib. |
| Loncastuximab | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Loncastuximab tesirine. |
| Loperamide | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Loperamide. |
| Lopinavir | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Lopinavir. |
| Lorlatinib | The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Lorlatinib. |
| Loxapine | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Loxapine. |
| Lumacaftor | The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Lumacaftor. |
| Lusutrombopag | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Lusutrombopag. |
| Maftivimab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Maftivimab. |
| Mannitol | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Mannitol. |
| Margetuximab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Margetuximab. |
| Maribavir | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Maribavir. |
| Mefloquine | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Mefloquine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Meloxicam. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Mepivacaine. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Mepolizumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| Methoxy polyethylene | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Inotuzumab ozogamicin. |
| Methylene blue | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Methylene blue. |
| Mifepristone | The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Mifepristone. |
| Mirabegron | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Mirabegron. |
| Mitapivat | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Mitapivat. |
| Mogamulizumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Mogamulizumab. |
| Morphine | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Morphine. |
| Mosunetuzumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Mosunetuzumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Inotuzumab ozogamicin. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Inotuzumab ozogamicin. |
| Necitumumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Necitumumab. |
| Neratinib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Neratinib. |
| Netupitant | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Netupitant. |
| Nilotinib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Nilotinib. |
| Nintedanib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Nintedanib. |
| Nivolumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Nivolumab. |
| Norgestimate | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Norgestimate. |
| Nortriptyline | The serum concentration of Nortriptyline can be increased when it is combined with Inotuzumab ozogamicin. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Inotuzumab ozogamicin. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Obinutuzumab. |
| Ocrelizumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ocrelizumab. |
| Odesivimab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Odesivimab. |
| Ofatumumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ofatumumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Olaratumab. |
| Omadacycline | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Omadacycline. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Inotuzumab ozogamicin. |
| Ombitasvir | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ombitasvir. |
| Osimertinib | The serum concentration of Osimertinib can be increased when it is combined with Inotuzumab ozogamicin. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Oxetacaine. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Oxybuprocaine. |
| Pacritinib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Pacritinib. |
| Palbociclib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Palbociclib. |
| Paliperidone | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Paliperidone. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Inotuzumab ozogamicin. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Inotuzumab ozogamicin. |
| Panobinostat | The serum concentration of Panobinostat can be increased when it is combined with Inotuzumab ozogamicin. |
| Paritaprevir | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Paritaprevir. |
| Pazopanib | The serum concentration of Pazopanib can be increased when it is combined with Inotuzumab ozogamicin. |
| Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Inotuzumab ozogamicin. |
| Pembrolizumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Pembrolizumab. |
| Pertuzumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Pertuzumab. |
| Pexidartinib | Inotuzumab ozogamicin may increase the hepatotoxic activities of Pexidartinib. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Phenol. |
| Pibrentasvir | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Pibrentasvir. |
| Pitolisant | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Pitolisant. |
| Polatuzumab vedotin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Polatuzumab vedotin. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| Pomalidomide | The serum concentration of Pomalidomide can be increased when it is combined with Inotuzumab ozogamicin. |
| Ponatinib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ponatinib. |
| Posaconazole | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Posaconazole. |
| Pralsetinib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Pralsetinib. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Pramocaine. |
| Pravastatin | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Pravastatin. |
| Prednisolone phosphate | The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Prednisolone phosphate. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Prilocaine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Procaine. |
| Propafenone | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Propafenone. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Proparacaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Propoxycaine. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| Quinidine | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Quinidine. |
| Quinine | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Quinine. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Inotuzumab ozogamicin. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Inotuzumab ozogamicin. |
| Ranolazine | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ranolazine. |
| Ravulizumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Ravulizumab. |
| Raxibacumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Raxibacumab. |
| Regorafenib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Regorafenib. |
| Relugolix | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Relugolix. |
| Reserpine | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Reserpine. |
| Reslizumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Reslizumab. |
| Revefenacin | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Revefenacin. |
| Rifampicin | The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Rifampicin. |
| Rifamycin | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Rifamycin. |
| Rimegepant | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Rimegepant. |
| Riociguat | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Riociguat. |
| Ripretinib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ripretinib. |
| Risankizumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Risankizumab. |
| Ritonavir | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ritonavir. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Inotuzumab ozogamicin. |
| Rivaroxaban | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Rivaroxaban. |
| Rolapitant | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Rolapitant. |
| Romidepsin | The serum concentration of Romidepsin can be increased when it is combined with Inotuzumab ozogamicin. |
| Romosozumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Romosozumab. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Ropivacaine. |
| Sacituzumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Sacituzumab govitecan. |
| Sapropterin | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Sapropterin. |
| Saquinavir | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Saquinavir. |
| Sarecycline | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Sarecycline. |
| Sarilumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Sarilumab. |
| Secukinumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Secukinumab. |
| Selexipag | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Selexipag. |
| Selumetinib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Selumetinib. |
| Sildenafil | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Sildenafil. |
| Silodosin | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Silodosin. |
| Siltuximab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Siltuximab. |
| Simeprevir | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Simeprevir. |
| Simvastatin | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Simvastatin. |
| Sirolimus | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Sirolimus. |
| Sitagliptin | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Sitagliptin. |
| Sofosbuvir | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Sofosbuvir. |
| Sorafenib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Sorafenib. |
| Sotagliflozin | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Sotagliflozin. |
| Sotorasib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Sotorasib. |
| Sotrovimab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Sotrovimab. |
| Spesolimab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Spesolimab. |
| St. John’s Wort | The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with St. John’s Wort. |
| Stiripentol | The excretion of Inotuzumab ozogamicin can be decreased when combined with Stiripentol. |
| Sulesomab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Sulesomab. |
| Sutimlimab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Sutimlimab. |
| Suvorexant | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Suvorexant. |
| Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| Tacrolimus | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Tacrolimus. |
| Tafasitamab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tafasitamab. |
| Talazoparib | The serum concentration of Talazoparib can be increased when it is combined with Inotuzumab ozogamicin. |
| Tamoxifen | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Tamoxifen. |
| Tazemetostat | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Tazemetostat. |
| Technetium | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Technetium Tc-99m sestamibi. |
| Tegaserod | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Tegaserod. |
| Telaprevir | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Telaprevir. |
| Temsirolimus | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Temsirolimus. |
| Tenofovir disoproxil | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Tenofovir disoproxil. |
| Tepotinib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Tepotinib. |
| Tetanus immune | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tetanus immune globulin, human. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Inotuzumab ozogamicin is combined with Tetracaine. |
| Tezacaftor | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Tezacaftor. |
| Tezepelumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tezepelumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Inotuzumab ozogamicin. |
| Ticagrelor | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ticagrelor. |
| Tildrakizumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tildrakizumab. |
| Tipranavir | The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Tipranavir. |
| Tisotumab vedotin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tisotumab vedotin. |
| Tivozanib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Tivozanib. |
| Tixagevimab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tixagevimab. |
| Tocilizumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tocilizumab. |
| Tolvaptan | The serum concentration of Tolvaptan can be increased when it is combined with Inotuzumab ozogamicin. |
| Topotecan | The serum concentration of Topotecan can be increased when it is combined with Inotuzumab ozogamicin. |
| Toremifene | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Toremifene. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Inotuzumab ozogamicin. |
| Tralokinumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tralokinumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Inotuzumab ozogamicin. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Trastuzumab deruxtecan. |
| Trastuzumab | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Trastuzumab emtansine. |
| Trazodone | The serum concentration of Inotuzumab ozogamicin can be decreased when it is combined with Trazodone. |
| Tremelimumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Tremelimumab. |
| Trilaciclib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Trilaciclib. |
| Trimipramine | The serum concentration of Trimipramine can be increased when it is combined with Inotuzumab ozogamicin. |
| Tucatinib | Tucatinib may decrease the excretion rate of Inotuzumab ozogamicin which could result in a higher serum level. |
| Ubrogepant | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Ubrogepant. |
| Umbralisib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Umbralisib. |
| Umeclidinium | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Umeclidinium. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Inotuzumab ozogamicin. |
| Valoctocogene roxaparvovec | The therapeutic efficacy of Valoctocogene roxaparvovec can be decreased when used in combination with Inotuzumab ozogamicin. |
| Vandetanib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Vandetanib. |
| Vardenafil | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Vardenafil. |
| Vedolizumab | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Vedolizumab. |
| Velpatasvir | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Velpatasvir. |
| Vemurafenib | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Vemurafenib. |
| Venetoclax | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Venetoclax. |
| Verapamil | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Verapamil. |
| Vinblastine | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Vinblastine. |
| Vincristine | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Vincristine. |
| Vinflunine | The serum concentration of Vinflunine can be increased when it is combined with Inotuzumab ozogamicin. |
| Voclosporin | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Voclosporin. |
| Vorapaxar | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Vorapaxar. |
| Voxilaprevir | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Voxilaprevir. |
Pregnancy and Lactation
US FDA pregnancy category Not Assigned:
Pregnancy
Drugs that have caused, are suspected to have caused, or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details.
The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help healthcare providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.
Lactation
The effects in the nursing infant are unknown. Women should not breastfeed during therapy and for at least 2 months after the last dose.
How should this medicine be used?
Inotuzumab ozogamicin injection comes as powder to be mixed with liquid to be injected intravenously (into a vein) by a doctor or nurse in a hospital or medical facility. It is usually injected on days 1, 8, and 15 of a 3- to 4-week cycle. The cycle may be repeated every 4 weeks as recommended by your doctor. The length of your treatment depends on how well your body responds to the medication and the side effects that you experience.
Your doctor may need to interrupt or stop your treatment, lower your dose, or treat you with additional medications, depending on your response to inotuzumab ozogamicin and any side effects that you experience. You will receive certain medications to help prevent a reaction before you receive each dose of inotuzumab ozogamicin. Tell your doctor or nurse if you experience any of the following symptoms during and for at least one hour after the end of infusion: fever, chills, rash, shortness of breath, or difficulty breathing. Talk to your doctor about how you are feeling during and after your treatment.
What special precautions should I follow?
Before using inotuzumab ozogamicin injection,
- tell your doctor and pharmacist if you are allergic to inotuzumab ozogamicin, any other medications, or any of the ingredients in inotuzumab ozogamicin injection. Ask your pharmacist for a list of the ingredients.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: amiodarone (Pacerone, Nexterone); chloroquine (Aralen); clarithromycin (Biaxin, in Prevpac); disopyramide (Norpace); erythromycin (E.E.S., E-Mycin, P.C.E, others); haloperidol; methadone (Dolophine, Methadose); nefazodone; pimozide (Orap); procainamide; quinidine (in Nuedexta); sotalol (Betapace, Betapace AF, Sorine); and thioridazine. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with inotuzumab ozogamicin, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
- tell your doctor if you or anyone in your family has or has ever had a prolonged QT interval (a rare heart problem that may cause irregular heartbeat, fainting, or sudden death). Also, tell your doctor if you have or have ever had a low level of potassium or magnesium in your blood or kidney disease.
- tell your doctor if you are pregnant or plan to become pregnant. If you are a female, you should not become pregnant while you are receiving inotuzumab ozogamicin and for at least 8 months after your final dose. Talk to your doctor about birth control methods that will work for you. If you are a male, you and your female partner should use birth control during your treatment and continue to use birth control for at least 5 months after your final dose. If you or your partner become pregnant while receiving inotuzumab ozogamicin, call your doctor. Inotuzumab ozogamicin may harm the fetus.
- tell your doctor if you are breastfeeding. Your doctor may tell you not to breastfeed during your treatment with inotuzumab ozogamicin injection and for at least 2 months after your final dose.
- you should know that this medication may decrease fertility in men and women. Talk to your doctor about the risks of receiving inotuzumab ozogamicin.
References
